Evidence map›Paper›PMID 36550213›Full record

ArticleLeukemia2023

Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival.

Richard T Silver, Katie Erdos, Elwood Taylor, Joseph M Scandura, Ghaith Abu-Zeinah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Richard T SilverRichard T Silver, MD Myeloproliferative Neoplasms Center, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA. rtsilve@med.cornell.edu.ORCID 0000-0002-8524-0964
Katie ErdosRichard T Silver, MD Myeloproliferative Neoplasms Center, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
Elwood TaylorRichard T Silver, MD Myeloproliferative Neoplasms Center, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
Joseph M ScanduraRichard T Silver, MD Myeloproliferative Neoplasms Center, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9525-143X
Ghaith Abu-ZeinahRichard T Silver, MD Myeloproliferative Neoplasms Center, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-1881-3670

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Polycythemia VeraPrimary MyelofibrosisClinical RelevanceHumansJanus Kinase 2SplenomegalyJanus Kinase 2

Identifiers

PMID36550213
PMCPMC10565714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.